Physician profile
John K Chan
NPI 1962596551
$1,980,545.72
in general payments reported to CMS, 2019-2025
29 companies · $338K in 2025
The $338K reported for 2025 was more than what 99% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $425K · 2020: $113K · 2021: $194K · 2022: $286K · 2023: $284K · 2024: $339K · 2025: $338K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $687K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $102K · Travel and Lodging: $79K · Consulting Fee: $79K · Food and Beverage: $15K · Education: $191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $687,415.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $101,962.50 |
| Travel and Lodging | $78,691.05 |
| Consulting Fee | $78,531.50 |
| Food and Beverage | $15,094.02 |
| Education | $190.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $605,274.09 | 2019-2025 | Lynparza, Enhertu |
| Glaxosmithkline, LLC. | $553,026.55 | 2020-2025 | Jemperli, Zejula |
| Eisai INC. | $216,477.86 | 2019-2025 | |
| Tesaro, INC. | $100,994.43 | 2019 | |
| Merck Sharp & Dohme LLC | $93,726.72 | 2019-2025 | Keytruda |
| Clovis Oncology, INC. | $82,697.96 | 2019-2021 | |
| Seagen INC. | $75,223.32 | 2020-2023 | Tivdak |
| Abbvie INC. | $73,843.05 | 2024-2025 | |
| Genmab U.S., INC. | $66,737.93 | 2022-2025 | Tivdak, Epkinly |
| Pfizer INC. | $46,752.90 | 2024-2025 | |
| Genentech USA, INC. | $18,780.58 | 2019 | |
| Immunogen, INC. | $18,425.03 | 2023 | Elahere |
| F. Hoffmann-La Roche Ag | $18,199.49 | 2019-2020 | |
| Myriad Genetic Laboratories, INC. | $5,958.82 | 2021-2025 | Mychoice Cdx, Precisetumor, Myrisk |
| Medical Device Business Services, INC. | $1,915.64 | 2021-2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai Co., Ltd. | $1,225.50 | 2025 | |
| Corcept Therapeutics | $439.96 | 2025 | Korlym |
| Ethicon US, LLC | $316.77 | 2021-2023 | Harmonic, Stratafix, Dermabond |
| Epizyme, INC. | $224.95 | 2021 | |
| Intuitive Surgical, INC. | $125.82 | 2025 | |
| Karyopharm Therapeutics INC. | $102.98 | 2024 | Xpovio |
| Eli Lilly and Company | $57.00 | 2025 | |
| Medtronic Vascular, INC. | $18.37 | 2019 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.